We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01121913
Recruitment Status : Completed
First Posted : May 12, 2010
Results First Posted : August 16, 2010
Last Update Posted : April 27, 2012
Sponsor:
Information provided by (Responsible Party):
Labopharm Inc.

Tracking Information
First Submitted Date  ICMJE May 10, 2010
First Posted Date  ICMJE May 12, 2010
Results First Submitted Date  ICMJE June 22, 2010
Results First Posted Date  ICMJE August 16, 2010
Last Update Posted Date April 27, 2012
Study Start Date  ICMJE March 2005
Actual Primary Completion Date April 2005   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 21, 2010)
  • Bioequivalence Based on AUC(0-t) [ Time Frame: 72 hours ]
    AUC(0-t) = Area under the plasma concentration curve vs (versus) time data pairs, where t is the time of the last quantifiable concentration. Measured in nanogram x hours per milliliter (ng*h/mL).
  • Bioequivalence Based on AUC(0-∞) [ Time Frame: 72 hours ]
    AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞). Measured in nanogram x hours per milliliter (ng*h/mL).
  • Bioequivalence Based on Cmax [ Time Frame: 72 hours ]
    Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).
Original Primary Outcome Measures  ICMJE
 (submitted: May 10, 2010)
  • Area under the plasma concentration [AUC(0-t)] vs time data pairs [ Time Frame: 72 hours ]
    Area under the plasma concentration [AUC(0-t)], vs (versus) time data pairs where t is the time of the last quantifiable concentration
  • Area under the plasma concentration vs time data pairs with extrapolation to infinity [AUC(0-∞)]
    Area under the plasma concentration vs time data pairs, with extrapolation to infinity [AUC(0-∞)]
  • Maximum concentration (Cmax) [ Time Frame: 72 hours ]
    Maximum concentration (Cmax) following each dose and the absolute Cmax are reported
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 21, 2010)
  • Apparent Terminal Half-life (t½.z) [ Time Frame: 72 hours ]
    Apparent terminal half-life (t½.z) of trazodone in hours
  • Time to the Maximum Concentration (Tmax) [ Time Frame: 72 hours ]
  • Apparent First Order Terminal Rate Constant [λz] [ Time Frame: 72 hours ]
    Apparent First order terminal rate constant [λz] of trazodone in plasma expressed in 1/hours.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 10, 2010)
  • Apparent terminal half-life (t½.z) [ Time Frame: 72 hours ]
    Apparent terminal half-life (t½.z)
  • Time to the maximum concentration (Tmax) [ Time Frame: 72 hours ]
    Time to the maximum concentration (Tmax) following each dose and the absolute Cmax are reported
  • Apparent First order terminal rate constant [λz] [ Time Frame: 72 hours ]
    Apparent First order terminal rate constant [λz]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers
Official Title  ICMJE A Randomized, Four-way Crossover Pilot Study to Compare the Relative Bioavailability of Two Prototype Once-a-day Trazodone Hydrochloride Products and Two Marketed Reference Products Following an Equivalent Daily Dose Administration Under Fasting Conditions in Healthy Volunteers
Brief Summary

The objectives of this study were:

  • to compare the pharmacokinetic profiles of two prototype controlled-release (CR) trazodone hydrochloride (HCl) 300 mg tablets versus two reference products: Trittico® AC (2 x 150 mg CR tablets) and Desyrel® (3 x 100 mg IR (immediate-release) tablets) under fasting condition;
  • to assess the controlled release properties of the two prototype formulations;
  • to select a prototype formulation for further development;
  • to validate the blood sampling schedule for future pivotal pharmacokinetic studies;
  • to determine the appropriate sample size for pivotal studies based in the intra-subject variability.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: Trazodone HCl
    The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
  • Drug: Trazodone HCl
    The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
    Other Name: Oleptro
  • Drug: Trazodone HCl
    The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
  • Drug: Trazodone HCl
    The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
Study Arms  ICMJE
  • Experimental: Trazodone Contramid® OAD (test product 1)
    Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
    Intervention: Drug: Trazodone HCl
  • Experimental: Trazodone Contramid® OAD(test product 2)
    Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
    Intervention: Drug: Trazodone HCl
  • Active Comparator: Triticco®
    Intervention: Drug: Trazodone HCl
  • Active Comparator: Desyrel®
    Intervention: Drug: Trazodone HCl
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 10, 2010)
24
Original Actual Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Actual Primary Completion Date April 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male and female subjects 18 to 45 years of age (inclusive).
  • Body mass within 10% of the ideal mass in relation to height and age, according to the BMI.
  • Body mass not less than 70 kg. The normal total circulating blood volume in males and in females is about 71 mL/kg and 65 mL/kg of the body mass, respectively (Meyer, 1988). No subject will have more than 13% of estimated blood volume taken during the study (Standards for the Practice of Blood Transfusion in South Africa, 1999).
  • Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the "normal ranges" for the relevant laboratory tests (unless the clinical investigator considers the deviation to be irrelevant for the purpose of the study).
  • Normal ECG and vital signs, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study.
  • Willingness to undergo pre- and post-study physical examinations, and pre- and post study laboratory investigations.
  • Ability to comprehend and willingness to sign both statements of informed consent (for screening and phase-related procedures).
  • Non-smoker or past smoker who stopped smoking at least 3 months before entering the study.
  • For females, the following conditions are to be met:

    1. has been surgically sterilized, or
    2. is of childbearing potential, and all of the following conditions are met:

      1. had a normal menstrual flow within 1 month before study entry, and
      2. has a negative urine pregnancy test at screening. If this test is positive, the subject will be excluded from the study before receiving study medication. In the rare circumstance that a pregnancy is discovered after the subjects received the study drug, every attempt must be made to follow such subjects to term, and
      3. must agree to use an accepted method of contraception (i.e., spermicide and barrier methods or spermicide and intrauterine contraceptive device). The subject must agree to continue with the same method throughout the study. Hormonal contraceptives will be allowed, with a stable dose for at least one month prior to the first intake of study medication.

Exclusion Criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • History of, or current compulsive alcohol abuse (> 10 drinks weekly), or regular exposure to other substances of abuse.
  • Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this will not affect the outcome of the study in the opinion of the clinical investigator. Use of hormonal contraceptive agents by females is allowed.
  • Participation in another study with an experimental drug within 8 weeks before the first administration of study medication.
  • Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
  • A major illness during the 3 months before commencement of the screening period.
  • History of hypersensitivity to the study drug or any related drugs.
  • History of bronchial asthma.
  • History of epilepsy.
  • Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
  • Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse rate of > 100 beats per minute or < 45 beats per minute during the screening period, either supine or standing.
  • Positive testing for HIV, hepatitis B surface antigen and/or Hepatitis C antibodies.
  • Positive urine screen for drugs of abuse.
  • A urine pregnancy test (ß-HCG) either positive or not performed or lactation.
  • Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step Cotinine (COT) Tests).
  • History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months prior to study start.
  • Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g. aspartate aminotransferase, alanine aminotransferase) >2 times the upper boundary of the normal range.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01121913
Other Study ID Numbers  ICMJE 04ACL101
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Labopharm Inc.
Original Responsible Party Vice-president Regulatory Affairs, Labopharm Inc.
Current Study Sponsor  ICMJE Labopharm Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Labopharm Inc.
Verification Date April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP